Research shows that the drug Imatinib, usually prescribed for Leukemia and gastric cancer, halves mortality and shortens the stay of Covid patients at the ICU by a week. Imatinib is especially effective in the 20 percent most ill Covid patients. However, further research is needed. Follow-up studies will be done by Amsterdam OLVG, the Erasmus Medical Center, the Dijklander Hospital and by the World Health Organisation in the Remapcap study.
Read more (in Dutch)
A smart swimming cap with electrodes can diagnose a stroke in the ambulance, so that a patient receives the correct treatment more quickly.News
VU start-up, PreActive, has been awarded the MIT Feasibility Study subsidy of € 20k from Provincie Noord-Holland! With this subsidy funding PreActive will explore the utility and feasibility of incorporating Artificial Intelligence within the PreActive wellness app to help improve & personalise the user experience. Feasibility study of the Wellness app The PreActive Wellness app […]News
UvA spin-off SusPhos has been selected for the EIC Accelerator funding. They receive a grant and an equity investment from the EU fund for its game-changing solution for upcycling phosphate from waste streams into sustainable products. SusPhos, now based in Leeuwarden, aims to create “urban mines” in Europe to produce phosphate compounds out of waste. […]News